<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742895</url>
  </required_header>
  <id_info>
    <org_study_id>7339-002</org_study_id>
    <secondary_id>MK-7339-002</secondary_id>
    <secondary_id>2018-003007-19</secondary_id>
    <secondary_id>LYNK-002</secondary_id>
    <secondary_id>194694</secondary_id>
    <nct_id>NCT03742895</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)</brief_title>
  <official_title>A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in&#xD;
      participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1)&#xD;
      have progressed or been intolerant to standard of care therapy; and 2) are positive for&#xD;
      homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 53 months</time_frame>
    <description>ORR is defined as the percentage of participants who achieve a confirmed complete response ([CR]; disappearance of all target lesions) or partial response ([PR]: ≥30% decrease in the sum of diameters of target lesions) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors 1.1, modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ (modified RECIST 1.1). For participants with prostate cancer, ORR will be based on Prostate Cancer Working Group (PCWG)-modified RECIST 1.1 as assessed by BICR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 53 months</time_frame>
    <description>DOR is defined as the time from first documented evidence of CR or PR until the first documented sign of disease progression or death due to any cause, whichever occurs first. DOR will be assessed by BICR according to either modified RECIST 1.1 or PCWG-modified RECIST 1.1 for participants with prostate cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 53 months</time_frame>
    <description>OS is defined as the time from the date of the first dose to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 53 months</time_frame>
    <description>PFS is defined as the time from the date of the first dose to either: 1) the first documented disease progression as assessed either by BICR according to modified RECIST 1.1 or PCWG-modified RECIST 1.1 for participants with prostate cancer; or 2) death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to 53 months</time_frame>
    <description>An AE is any unfavorable and unintended sign, symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing an AE will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE)</measure>
    <time_frame>Up to 52 months</time_frame>
    <description>The number of participants discontinuing study treatment due to an AE will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in Participants with HRRm or HRD Positive Cancer</measure>
    <time_frame>Up to 53 months</time_frame>
    <description>For participants with homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD) positive cancer, the ORR will be assessed. ORR is defined as the percentage of participants who achieve a confirmed complete response ([CR]; disappearance of all target lesions) or partial response ([PR]: ≥30% decrease in the sum of diameters of target lesions) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors 1.1, modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ (modified RECIST 1.1). For participants with prostate cancer, ORR will be based on Prostate Cancer Working Group (PCWG)-modified RECIST 1.1 as assessed by BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Earliest Progression by Cancer Antigen-125 (CA-125)</measure>
    <time_frame>Up to 53 months</time_frame>
    <description>For participants with BRCA1/2 non-mutated ovarian cancer only, the time to earliest progression by CA-125 will be assessed. Progression by CA-125 is defined as an increase in CA-125 level ≥2x upper limit normal (ULN) on 2 occasions, 1 week apart. For participants with elevated CA-125 (≥ULN) at baseline, progression by CA-125 is defined as an increase in CA-125 level ≥2x the nadir value on 2 occasions, 1 week apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific Antigen (PSA) Response Rate in Participants with Prostate Cancer</measure>
    <time_frame>Up to 53 months</time_frame>
    <description>For participants with prostate cancer, the PSA response rate will be presented. PSA response rate is defined as the percentage of participants in the analysis population with PSA reduction of ≥50% from baseline measured twice at least 3 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival After Next-Line Treatment in Participants with sBRCAm Breast Cancer</measure>
    <time_frame>Up to 53 months</time_frame>
    <description>For participants with somatic BRCA mutated (sBRCAm) breast cancer, the PFS after next-line treatment will be presented. PFS is defined as the time from the date of the first dose to either: 1) the first documented disease progression on the next-line of treatment, as assessed by BICR according to modified RECIST 1.1; or 2) death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Advanced Solid Neoplasms</condition>
  <arm_group>
    <arm_group_label>Olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HRRm or HRD-positive advanced cancer will receive oral olaparib, 300 mg twice daily (BID).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Olaparib 300 mg administered BID as two, 150 mg oral tablets.</description>
    <arm_group_label>Olaparib</arm_group_label>
    <other_name>MK-7339</other_name>
    <other_name>AZD2281</other_name>
    <other_name>KU-0059436</other_name>
    <other_name>LYNPARZA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For all participants:&#xD;
&#xD;
          -  Has measurable disease per RECIST 1.1 or PCWG-modified RECIST 1.1 as assessed by the&#xD;
             local site Investigator/radiology and confirmed by BICR.&#xD;
&#xD;
          -  Is able to provide a newly obtained core or excisional biopsy of a tumor lesion or&#xD;
             either an archival formalin-fixed paraffin embedded (FFPE) tumor tissue block or&#xD;
             slides.&#xD;
&#xD;
          -  Has a life expectancy of at least 3 months.&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1,&#xD;
             as assessed within 7 days of treatment initiation.&#xD;
&#xD;
          -  Male participants must agree to use contraception during the treatment period and for&#xD;
             at least 95 days (3 months and 5 days) after the last dose of study treatment and&#xD;
             refrain from donating sperm during this period.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               1. Is not a woman of childbearing potential (WOCBP).&#xD;
&#xD;
               2. Is a WOCBP and using a contraceptive method that is highly effective with low&#xD;
                  user dependency, or be abstinent from heterosexual intercourse as their preferred&#xD;
                  and usual lifestyle (abstinent on a long term and persistent basis), during the&#xD;
                  intervention period and for at least 180 days after the last dose of study&#xD;
                  intervention, AND agrees not to donate eggs (ova, oocytes) to others or&#xD;
                  freeze/store for her own use for the purpose of reproduction during this period.&#xD;
&#xD;
          -  Has adequate organ function.&#xD;
&#xD;
          -  For participants who have non-breast or -ovarian cancers that are breast cancer&#xD;
             susceptibility gene 1/2 (BRCA1/2) mutated (BRCAm), or who have cancers that are&#xD;
             BRCA1/2 non-mutated and homologous recombination repair nonmutated:&#xD;
&#xD;
          -  Has a histologically- or cytologically-confirmed advanced (metastatic and/or&#xD;
             unresectable) solid tumor (except ovarian cancer whose tumor has a germline or somatic&#xD;
             BRCA mutation and breast cancer whose tumor has a germline BRCA mutation) that is not&#xD;
             eligible for curative treatment and for which standard of care therapy has failed.&#xD;
             Participants must have progressed on or be intolerant to standard of care therapies&#xD;
             that are known to provide clinical benefit. There is no limit on the number of prior&#xD;
             treatment regimens.&#xD;
&#xD;
          -  Has either centrally-confirmed known or suspected deleterious mutations in at least 1&#xD;
             of the genes involved in HRR or centrally-confirmed HRD.&#xD;
&#xD;
          -  For participants receiving prior platinum (cisplatin, carboplatin, or oxaliplatin&#xD;
             either as monotherapy or in combination) for advanced (metastatic and/or unresectable)&#xD;
             solid tumor, have no evidence of disease progression during the platinum chemotherapy&#xD;
             or ≤4 weeks of completing the platinum-containing regimen.&#xD;
&#xD;
          -  For participants who have somatic BRCAm breast cancer:&#xD;
&#xD;
          -  Has histologically- or cytologically-confirmed breast cancer with evidence of&#xD;
             metastatic disease.&#xD;
&#xD;
          -  Has a centrally-confirmed known or suspected deleterious mutation in breast cancer&#xD;
             susceptibility gene (BRCA) 1 or BRCA2 and does not harbor a germline BRCA1 or BRCA2&#xD;
             mutation.&#xD;
&#xD;
          -  Has received treatment with an anthracycline unless contraindicated and a taxane in&#xD;
             either the neoadjuvant/adjuvant or metastatic setting.&#xD;
&#xD;
          -  Participants with estrogen and/or progesterone receptor-positive disease must have&#xD;
             received and progressed on at least one endocrine therapy (adjuvant or metastatic), or&#xD;
             have disease that the treating physician believes to be inappropriate for endocrine&#xD;
             therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             in the last 5 years. Note: Participants with basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, ductal carcinoma in situ, or cervical carcinoma&#xD;
             in situ that has undergone potentially curative therapy are not excluded.&#xD;
&#xD;
          -  Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features&#xD;
             suggestive of MDS/AML.&#xD;
&#xD;
          -  Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.&#xD;
             Note: Participants with previously treated brain metastases may participate if&#xD;
             radiologically stable, clinically stable, and without requirement for steroid&#xD;
             treatment for at least 14 days prior to the first dose of study treatment.&#xD;
&#xD;
          -  Has received colony-stimulating factors (e.g., granulocyte colony-stimulating factor&#xD;
             [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF] or recombinant&#xD;
             erythropoietin) within 28 days prior to the first dose of study treatment.&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Has known active hepatitis infection (i.e., Hepatitis B or C).&#xD;
&#xD;
          -  Is unable to swallow orally administered medication or has a gastrointestinal disorder&#xD;
             affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption).&#xD;
&#xD;
          -  Has received prior therapy with olaparib or with any other polyadenosine 5'&#xD;
             diphosphoribose (poly[ADP ribose]) polymerization (PARP) inhibitor.&#xD;
&#xD;
          -  Has a known hypersensitivity to the components or excipients in olaparib.&#xD;
&#xD;
          -  Has received previous allogenic bone-marrow transplant or double umbilical cord&#xD;
             transplantation (dUCBT).&#xD;
&#xD;
          -  Has received a whole blood transfusion in the last 120 days prior to entry to the&#xD;
             study. Packed red blood cells and platelet transfusions are acceptable if not&#xD;
             performed within 28 days of the first dose of study treatment.&#xD;
&#xD;
          -  Has received any anti-neoplastic systemic chemotherapy or biological therapy, targeted&#xD;
             therapy, or an anticancer hormonal therapy within 3 weeks prior to the first dose of&#xD;
             study intervention.&#xD;
&#xD;
          -  Has a primary cancer of unknown origin.&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks of start of study intervention.&#xD;
             Participants must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted&#xD;
             for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center - North Campus ( Site 0011)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>520-694-9049</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare-Oncology ( Site 0056)</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>7149923000x4332</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center ( Site 0002)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-248-7443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-885-7604</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0092)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>303-399-8020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University ( Site 0025)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-778-4383</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta University ( Site 0028)</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>706-721-4430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Markey Cancer Center ( Site 0018)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>859-257-9568</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland ( Site 0050)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-328-7224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Institute at Franklin Square ( Site 0054)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-777-7364</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts ( Site 0017)</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System ( Site 0060)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-9826</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Partners of Nebraska ( Site 0051)</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>402-327-7363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0116)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-5089</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0126)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-5089</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA New York Harbor Healthcare System Manhattan ( Site 0094)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>21268675003303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0057)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-731-7921</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center ( Site 0026)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-5089</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwestern Regional Medical Center, Inc. ( Site 0079)</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Eastern Regional Medical Center, Inc. ( Site 0077)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sanford Hematology Oncology-Sioux Falls SD ( Site 0012)</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>605-328-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare ( Site 0043)</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>435-251-4742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center ( Site 0052)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-287-6272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0093)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-277-3101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 2703)</name>
      <address>
        <city>Berazategui</city>
        <state>Buenos Aires</state>
        <zip>B1884BBF</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>541142262013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico de Buenos Aires ( Site 2704)</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <state>Caba</state>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541143096897</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Metabolicas ( Site 2700)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541146356624</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Aleman ( Site 2702)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+54 11 4827-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinghorn Cancer Centre ( Site 2200)</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61293555655</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MNCCI Port Macquarie Base Hospital ( Site 2201)</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61265801818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd ( Site 2202)</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61864573333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre ( Site 0210)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4164805000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0203)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>51425234005853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital ( Site 0209)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5143408222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 0204)</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4185254444x20414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Centro de Investigacion Clinica CIC ( Site 2812)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050021</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573122885210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rodrigo Botero SAS ( Site 2801)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050030</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5743490799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Biomelab S A S ( Site 2800)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2808)</name>
      <address>
        <city>Valledupar</city>
        <state>Cesar</state>
        <zip>200001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5755602310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica S.A. ( Site 2806)</name>
      <address>
        <city>Monteria</city>
        <state>Cordoba</state>
        <zip>230002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573157962122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Administradora Country SA - Clinica del Country ( Site 2802)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5300470 Ext.: 2909</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 2807)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110311</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573016410749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia E.S.E ( Site 2809)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110321</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5714320160Ext4217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>C. Medico Imbanaco Cali S.A. ( Site 2810)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet ( Site 0402)</name>
      <address>
        <city>Copenhagen</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+45 35 45 35 45</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev og Gentofte Hospital. ( Site 0401)</name>
      <address>
        <city>Herlev</city>
        <state>Hovedstaden</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+45 38 68 38 68</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital ( Site 0400)</name>
      <address>
        <city>Odense</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4565413238</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers ( Site 0612)</name>
      <address>
        <city>Poitiers</city>
        <state>Ain</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33549441496</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne ( Site 0610)</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33492031514</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Strasbourg Europe ( Site 0613)</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33388252485</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc ( Site 0608)</name>
      <address>
        <city>Dijon</city>
        <state>Bourgogne</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33380737506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie ( Site 0603)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556333333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy ( Site 0601)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142114296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Regional de Sub Especialidades Medicas SA ( Site 3003)</name>
      <address>
        <city>Guatemala</city>
        <state>Quetzaltenango</state>
        <zip>09001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50259450559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 3004)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50259458053</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Integra Cancer Institute ( Site 3006)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50222790939</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grupo Angeles SA ( Site 3001)</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50240492110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital ( Site 1654)</name>
      <address>
        <city>Dublin</city>
        <state>Carlow</state>
        <zip>D07 WKW8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+353018034838</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bon Secours Hospital ( Site 1656)</name>
      <address>
        <city>Cork</city>
        <zip>T12 DV56</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+353214345495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital ( Site 1653)</name>
      <address>
        <city>Dublin</city>
        <zip>00004</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35314144259</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tallaght University Hospital ( Site 1652)</name>
      <address>
        <city>Dublin</city>
        <zip>D24 NROA</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35314144259</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 0800)</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>8457108</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97286400060</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0801)</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247773003</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem Medical Center ( Site 0802)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226777825</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 0803)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235302243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 0804)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236973082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione Pascale ( Site 0700)</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390815903431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas Research Hospital ( Site 0703)</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390282244080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Le Scotte di Siena ( Site 0704)</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390577586335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital ( Site 2602)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 2600)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital ( Site 2604)</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital ( Site 2603)</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital ( Site 2601)</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR ( Site 2605)</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 2402)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82317877022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 2401)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220720850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 2400)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222288132</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Actualidad Basada en la Investigacion del Cancer ( Site 2903)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44680</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523313141707</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad Biomedica Avanzada Monterrey S. A. ( Site 2902)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cuidados Oncologicos ( Site 2908)</name>
      <address>
        <city>Santiago De Quetaro</city>
        <state>Queretaro</state>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+524422428555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 2901)</name>
      <address>
        <city>Madero</city>
        <state>Tamaulipas</state>
        <zip>89440</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centro Estatal de Cancerologia de Chihuahua ( Site 2907)</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+526144106742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consultorio de Medicina Especializada del Sector Privado ( Site 2904)</name>
      <address>
        <city>Mexico City</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5215529009882</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 2900)</name>
      <address>
        <city>Mexico City</city>
        <zip>06100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525555743589</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oaxaca Site Management Organization S.C. ( Site 2905)</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5209515147056</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 3102)</name>
      <address>
        <city>Trujillo</city>
        <state>La Libertad</state>
        <zip>13006</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51964820298</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas ( Site 3106)</name>
      <address>
        <city>Lima</city>
        <state>Muni Metro De Lima</state>
        <zip>15038</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51999389433</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Guillermo Almenara Irigoyen ( Site 3107)</name>
      <address>
        <city>Lima</city>
        <zip>15033</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51983716192</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Internacional Sede San Borja ( Site 3100)</name>
      <address>
        <city>Lima</city>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51999611475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia y Radioterapia Clinica Ricardo Palma ( Site 3101)</name>
      <address>
        <city>Lima</city>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5112241598 Ext.121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Central de la Fuerza Aerea del Peru ( Site 3104)</name>
      <address>
        <city>Lima</city>
        <zip>15046</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51997346037</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Militar Central Coronel Luis Arias Schereiber ( Site 3105)</name>
      <address>
        <city>Lima</city>
        <zip>15076</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51997468543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Arzobispo Loayza ( Site 3103)</name>
      <address>
        <city>Lima</city>
        <zip>15082</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51987421693</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C. Pelican Impex S.R.L Spitalul Clinic Pelican Oradea ( Site 1102)</name>
      <address>
        <city>Oradea</city>
        <state>Bihor</state>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40259444444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisprof ( Site 1107)</name>
      <address>
        <city>Cluj Napoca</city>
        <state>Cluj</state>
        <zip>400641</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40264705150/51</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SC Radiotherapy Center Cluj SRL ( Site 1105)</name>
      <address>
        <city>Comuna Floresti</city>
        <state>Cluj</state>
        <zip>407280</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40742206212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103)</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40727774974</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul PDR Medlife ( Site 1106)</name>
      <address>
        <city>Brasov</city>
        <zip>500152</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>40724789294</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C.Focus Lab Plus S.R.L ( Site 1101)</name>
      <address>
        <city>Bucuresti</city>
        <zip>022548</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40721298677</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C.Gral Medical S.R.L ( Site 1104)</name>
      <address>
        <city>Bucuresti</city>
        <zip>031422</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40723954705</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Clinical Oncological Dispensary ( Site 1204)</name>
      <address>
        <city>Arkhangelsk</city>
        <state>Arkhangel Skaya Oblast</state>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79212469153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1212)</name>
      <address>
        <city>Chelyabinsk</city>
        <state>Chelyabinskaya Oblast</state>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79127949047</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 1216)</name>
      <address>
        <city>Krasnogorsk</city>
        <state>Moskovskaya Oblast</state>
        <zip>143442</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74957305726</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin NMRCO ( Site 1201)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115477</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79031990755</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 1213)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79262110975</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ryazan Regional Clinical Oncology dispensary ( Site 1202)</name>
      <address>
        <city>Ryazan</city>
        <state>Ryazanskaya Oblast</state>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>SBHI Samara Regional Clinical Oncology Dispensary ( Site 1211)</name>
      <address>
        <city>Samara</city>
        <state>Samarskaya Oblast</state>
        <zip>443031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1208)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219437168</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Saint Luka ( Site 1205)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>SBHI Leningrad Regional Clinical Hospital ( Site 1206)</name>
      <address>
        <city>St.Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1207)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79179315577</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid ( Site 1352)</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914521987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d Hebron ( Site 1350)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934894158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zuerich ( Site 1400)</name>
      <address>
        <city>Zuerich</city>
        <state>Aargau</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41442552214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve HUG. ( Site 1406)</name>
      <address>
        <city>Geneva</city>
        <state>Geneve</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41795532353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Bellinzona e Valli ( Site 1407)</name>
      <address>
        <city>Bellinzona</city>
        <state>Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41918118194</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Necmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 1507)</name>
      <address>
        <city>Konya</city>
        <state>Adana</state>
        <zip>42080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903322237000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baskent University Adana Training Hospital ( Site 1508)</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905353067506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tıp Fakultesi ( Site 1503)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+9031230543304336</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akdeniz Universitesi Tip Fakultesi ( Site 1504)</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905052312377</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trakya Universitesi Tip Fakultesi ( Site 1500)</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322480988</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1505)</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905052312377</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1506)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902165664000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi ( Site 1502)</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323903911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital ( Site 1607)</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+44114226522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital ( Site 1606)</name>
      <address>
        <city>Oxford</city>
        <state>Worcestershire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441865227212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie NHS Foundation Trust ( Site 1601)</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441642282516</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Care ( Site 1602)</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441912138476</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Guatemala</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trial Information</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

